Irakurriaren ulermenaren zailtasunak bigarren hezkuntzan

(FR)Ce texte reprend la question de la compréhension de lecture et la faible note que nos étudiants du secondaire donnent à ce secteur, d’après PISA. De plus en plus de voix s’élèvent pour réclamer que la compréhension de lecture soit une des tâches de tous les professeurs et plus seulement des professeurs de langue et littérature. Lors de la préparation au métier d’enseignant, de plus en plus de cours sont organisés en rapport avec cette question de plus en plus préoccupante dans ce secteur. Les données sont celles-ci et toutes les tentatives pour résoudre ce problème semblent insuffisantes si on ne reprend pas la question au niveau du Curriculum et si on prépare les professeurs aux stratégies de lecture pour que les élèves parviennent à être des lecteurs compétents.

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

Background The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is a humanized monoclonal antibody that recognizes the EGFR extracellular domain and reaches Central Nervous System tumors, in nonclinical and clinical setting. While it has similar activity when compared to other anti-EGFR antibodies, it does not induce skin toxicity or hypomagnesemia. Methods A randomized, double blind, multicentric clinical trial was conducted in high grade glioma patients (41 anaplastic astrocytoma and 29 glioblastoma multiforme) that received radiotherapy plus nimotuzumab or placebo. Treatment and placebo groups were well-balanced for the most important prognostic variables. Patients received 6 weekly doses of 200 mg nimotuzumab or placebo together with irradiation as induction therapy. Maintenance treatment was given for 1 year with subsequent doses administered every 3 weeks. The objectives of this study were to assess the comparative overall survival, progression free survival, response rate, immunogenicity and safety. Results The median cumulative dose was 3200 mg of nimotuzumab given over a median number of 16 doses. The combination of nimotuzumab and RT was well-tolerated. The most prevalent related adverse reactions included nausea, fever, tremors, anorexia and hepatic test alteration. No anti-idiotypic response was detected, confirming the antibody low immunogenicity. The mean and median survival time for subjects treated with nimotuzumab was 31.06 and 17.76 vs. 21.07 and 12.63 months for the control group. Conclusions In this randomized trial, nimotuzumab showed an excellent safety profile and significant survival benefit in combination with irradiation.